Gregory T. Went Sells 4,541 Shares of Adamas Pharmaceuticals Inc (ADMS) Stock
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) CEO Gregory T. Went sold 4,541 shares of the business’s stock in a transaction on Wednesday, March 21st. The shares were sold at an average price of $25.75, for a total transaction of $116,930.75. Following the sale, the chief executive officer now directly owns 182,610 shares in the company, valued at $4,702,207.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Adamas Pharmaceuticals stock traded down $1.34 during midday trading on Thursday, hitting $24.46. 566,435 shares of the stock were exchanged, compared to its average volume of 1,103,719. Adamas Pharmaceuticals Inc has a 1-year low of $13.50 and a 1-year high of $44.00. The company has a debt-to-equity ratio of 1.55, a current ratio of 10.79 and a quick ratio of 10.69. The firm has a market capitalization of $698.33, a P/E ratio of -6.18 and a beta of 1.59.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.09). The firm had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.84 million. During the same quarter in the previous year, the business earned ($0.68) earnings per share. The company’s revenue was up 1435.1% compared to the same quarter last year. analysts anticipate that Adamas Pharmaceuticals Inc will post -6.03 EPS for the current fiscal year.
ADMS has been the topic of several recent analyst reports. Northland Securities initiated coverage on shares of Adamas Pharmaceuticals in a research note on Wednesday, November 29th. They set an “outperform” rating on the stock. Cowen set a $55.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, December 13th. BidaskClub downgraded shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 14th. Piper Jaffray Companies set a $52.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, December 19th. Finally, Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $45.14.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/03/22/gregory-t-went-sells-4541-shares-of-adamas-pharmaceuticals-inc-adms-stock.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.